Key facts
- This page summarizes Marianne de Backer's Form 4 filing for Vir Biotechnology, Inc. (VIR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 30 Apr 2026, 17:43.
Marianne de Backer - 29 Apr 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- VIR
- Reported as of
- 29 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Apr 2026, 17:43:20 UTC
- Prior SEC filing
- 07 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Marianne de Backer filed Form 4 for Vir Biotechnology, Inc. (VIR) on 30 Apr 2026.
Change
- Previous filing in this sequence was filed on 07 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001797819
Primary reporting owner
De Backer Marianne
- Relationship
- President and CEO, Director
- Address
- C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
- Signature
- /s/ Vanina de Verneuil, Attorney-In-Fact
- Signature date
- 30 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIR
transaction
Common Stock
Other
- Transaction value
- Shares
- -233,532
- Change %
- -25%
- Price
- $0.000000*
- Shares after
- 714,613
- Date
- 29 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
VIR
transaction
Common Stock
Other
- Transaction value
- Shares
- +233,532
- Change %
- +440%
- Price
- $0.000000*
- Shares after
- 286,650
- Date
- 29 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Transfer without consideration for tax and estate planning purposes.
Footnote F2
The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.